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We read with interest the article by Gifford et al. “Iron
supplementation does not worsen respiratory health or alter the
sputum microbiome in cystic fibrosis”, published in the Journal
of Cystic Fibrosis [1]. In this double-blind cross-over randomised
placebo-controlled trial, the authors show that 6 weeks of oral
iron supplementation does not worsen respiratory health but fail
to correct anaemia. This is in contrast to our earlier report that
intravenous iron improves haemoglobin but may carry the risk of
worsening respiratory infection [2].
One reason for this contrast is the different routes of iron
supplementation. Hepcidin is an antimicrobial-like peptide
hormone synthesised by the liver that acts as the ‘master
regulator’ of iron metabolism [3]. Hepcidin level increases after
acute administration of oral iron supplementation to reduce
duodenal iron absorption and sequester iron in the reticuloendo-
thelial system [3,4]. This is a protective mechanism to protect
against infection, since most human pathogens are iron dependent
[3]. Intravenous iron may overwhelm iron withholding mecha-
nisms, increase lung iron content and increase susceptibility to
infection.
Another reason for this contrast is that every patient in our
case series received standard treatment for CF exacerbation [2].
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may improve haemoglobin [5,6]. Gifford et al. demonstrated
significant improvement in participants' serum iron level even
with low dose oral iron and high serum hepcidin-25 concentra-
tions [1]. Therefore, improving serum iron level alone may not be
enough to improve haemoglobin level among people with CF.
Interleukin-6 (IL-6) is abundant in the blood of people with CF
[7]. IL-6 represses erythropoietin-dependent maturation of
erythroid cell lines and limits haemoglobin synthesis [8]. IL-6
levels fall during the treatment of CF exacerbation [7], which
may explain the improvement in haemoglobin.
Another report in the Journal of Cystic Fibrosis has highlighted
the importance of accurately assessing systemic iron status to
avoid injudicious iron supplementation [9]. There may be a risk of
respiratory deterioration if oral iron supplementation is continued
after the subject has become iron replete, which is not assessed in
Gifford et al.'s short (6-week) study [1].
Iron deficiency anaemia remains an important clinical
issue for people with CF and further studies on its optimal
management are needed. Gifford et al. suggested that a larger
randomised controlled trial is needed to demonstrate the safety
of oral iron [1]. We suggest that a similar trial of intravenous
iron is also needed.References
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